BioSpace News Archive

bioMérieux announces the launch of GENE-UP® BREWPRO™ Yeast Slurry - the first-of-its-kind diagnostic quality control PCR test designed to specifically detect contaminants in raw yeast materials and yeast propagations to ensure top quality fermentations.

Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.

The Lung Cancer Mutation Consortium, facilitated by the Lung Cancer Research Foundation, announces the enrollment of one hundred patients in its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer, examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

Proscia®, a leading provider of digital and computational pathology solutions, has earned ISO 27001 certification. This certification demonstrates the company’s compliance

An artificial intelligence tool effectively detected distress in hospital workers’ conversations with their therapists early in the pandemic, a new study shows, suggesting a potential new technology that screens for depression and anxiety.

RG6501 (OpRegen ® ) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting.

Nutcracker Therapeutics, Inc. today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and CCR4.

Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, today announced the results of a clinical study published in the Cardiovascular Digital Health Journal.

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors.

Scorpion Therapeutics, Inc. today announced the appointment of Jeff Albers as a strategic advisor to the company.